Year: 2018
Type: review
Abstract: The ability of a cell to undergo mitochondrial apoptosis is governed by pro- and anti-apoptotic members of the BCL-2 protein family. The equilibrium of pro- versus anti-apoptotic BCL-2 proteins ensures appropriate regulation of programmed cell death during development and maintains organismal health. When unbalanced, the BCL-2 family can act as a barrier to apoptosis and facilitate tumour development and resistance to cancer therapy. Here we discuss the BCL-2 family, their deregulation in cancer and recent pharmaceutical developments to target specific members of this family as cancer therapy.
Source: Open Biology
DOI: 10.1098/rsob.180002
Authors: Kirsteen J. Campbell, Stephen W. G. Tait
Institutions: Cancer Research UK Scotland Institute, University of Glasgow
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,839
OpenAlex ID: W2804985859
